Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 128 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MEDI4736 + Tremelimumab Clear all
Active, not recruiting Phase 1 Interventional

SIRT With Tremelimumab and Durvalumab for Resectable HCC

NCT05701488
View directory record Official record
Conditions
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
Interventions
Durvalumab, Tremelimumab, SIRT
Drug · Device
Lead sponsor
Jiping Wang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

NCT02536794
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Anti-B7H1 Monoclonal Antibody MEDI4736, Laboratory Biomarker Analysis, Pharmacological Study, Tremelimumab
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 7, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

NCT02701400
View directory record Official record
Conditions
Recurrent Small Cell Lung Carcinoma
Interventions
Durvalumab, Hypofractionated Radiation Therapy, Stereotactic Body Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 7, 2026, 2:52 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT03298451
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT03522584
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy, Tremelimumab, Hypofractionated Image-Guided Radiation Therapy
Biological · Other · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 7, 2026, 2:52 AM EDT
Recruiting Phase 1 Interventional

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

NCT06058663
View directory record Official record
Conditions
Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Angiography, Biopsy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Positron Emission Tomography, Tremelimumab, Yttrium-90 Microsphere Radioembolization
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Durvalumab and Tremelimumab for Pediatric Malignancies

NCT03837899
View directory record Official record
Conditions
Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
Interventions
Durvalumab / Tremelimumab Combination Therapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Not yet recruiting Phase 2 Interventional

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

NCT06855225
View directory record Official record
Conditions
Combined Hepatocellular and Cholangiocarcinoma
Interventions
Tremelimumab, Durvalumab, Gemcitabine, Cisplatin
Drug
Lead sponsor
Mehmet Akce
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

NCT03005002
View directory record Official record
Conditions
Metastatic Carcinoma in the Liver, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 7, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

NCT03084471
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Santa Rosa, California • Washington D.C., District of Columbia • Tinley Park, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 7, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

NCT03430895
View directory record Official record
Conditions
Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Metastatic Bladder Cancer
Interventions
durvalumab and tremelimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 7, 2026, 2:52 AM EDT
Recruiting Phase 2 Interventional

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

NCT06698250
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Zanzalintinib, Durvalumab, Tremelimumab
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 7, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

NCT01975831
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer, Renal Cell Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
6
States / cities
New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 7, 2026, 2:52 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

NCT02542293
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma NSCLC
Interventions
Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
15
States / cities
Anaheim, California • San Diego, California • Santa Rosa, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

NCT03539822
View directory record Official record
Conditions
Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
Interventions
Cabozantinib, Durvalumab, Tremelimumab
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
2
States / cities
Westwood, Kansas • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

NCT03682068
View directory record Official record
Conditions
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
Interventions
Durvalumab, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Bakersfield, California • Fullerton, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

NCT03601455
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8
Interventions
Durvalumab, External Beam Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03026062
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Interventions
Durvalumab, Tremelimumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

NCT02453282
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma NSCLC
Interventions
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
35
States / cities
Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Active, not recruiting Phase 1 Interventional

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

NCT03923270
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, Olaparib Pill, Thoracic Radiotherapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)

NCT04989218
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
Novel combination of chemotherapy and immunotherapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 7, 2026, 2:52 AM EDT
Recruiting Phase 2 Interventional

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

NCT07174570
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Celecoxib, Durvalumab, Tremelimumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Biopsy Procedure
Drug · Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 7, 2026, 2:52 AM EDT
Recruiting Phase 2 Interventional

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

NCT04430452
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions
Durvalumab, Hypofractionated Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Mary Feng, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 7, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

NCT02352948
View directory record Official record
Conditions
Non - Small Cell Lung Cancer NSCLC
Interventions
MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
33
States / cities
Chandler, Arizona • Anaheim, California • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 7, 2026, 2:52 AM EDT